Wegovy (semaglutide) is a GLP-1 receptor agonist licensed for weight management that commonly causes gastrointestinal side effects including nausea, diarrhoea, and constipation
Overall worth it
In their paper on the study, published in JAMA Ophthalmology , the researchers noted that the substantially increased risk of NAION observed in patients on semaglutide appears not to be due to differences in baseline characteristics between the cohorts. They proposed the possibility that expression of the GLP-1 receptor in the human optic nerve and GLP-1 RA-induced enhanced sympathetic nervous system activity might influence optic nerve head perfusion and potentially increase the risk of NAION. Another notable finding was that the greatest risk of NAION appeared to be within the first year following the prescription of semaglutide, a temporal association that supports a potential drug-induced risk of NAION, the researchers pointed out
HIMS MAKES CASE FOR MORE CHOICE Hims said the treatment can be tailored for patients aiming to mitigate side effects or who prefer a pill over the injectable option
Barbagallo M, Dominguez LJ, Tagliamonte MR, Resnick LM, Paolisso G
Appetite suppression may be strongest in the days following injection and slightly less pronounced before the next dose, though individual experiences vary
